Abstracts tagged "DMARDs"

Abstract Number: 614 • 2018 ACR/ARHP Annual Meeting
Disease Activity One Year after Addition of Bucillamine or Sulfasaladine to Methotrexate in Japanese Patients with Rheumatoid Arthritis : Propensity Score Analysis
Genki Kidoguchi¹ and Kenichiro Tokunaga², ¹General internal medicine, Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan, ²Japanese Red Cross Kumamoto Hospital, Kumamoto, Japan
Background/Purpose: Bucillamine (BUC) is a small-molecule disease-modifying antirheumatic drug (DMARD) developed in Japan. The efficacy of combination therapy with BUC and methotrexate (MTX) has been demonstrated…
Abstract Number: 1520 • 2018 ACR/ARHP Annual Meeting
DMARD Hepatotoxicity in Rheumatoid Arthritis and Its Association with the Surrogates of Metabolic Syndrome
Abhishek Nandan¹, Huzaefah Syed¹, Josna Haritha², David Maniscalco¹, Rabia Gill¹, Puneet Puri¹ and Vivana Rodriguez¹, ¹Virginia Commonwealth University Health System, Richmond, VA, ²University of Chicago Medicine, Chicago, IL
Background/Purpose: Hepatotoxicity is a common reason why DMARDs are abandoned or changed in RA. We hypothesize that features of metabolic syndrome (such as obesity, dyslipidemia,…
Abstract Number: 2452 • 2018 ACR/ARHP Annual Meeting
Incidence Rate and Clinical Characteristics of Herpes Zoster Infection in Korean Patients with Rheumatoid Arthritis Patients
Su-Jin Moon¹, Min Jung Kim², Sun Kyung Lee², So Hee Oh², Hyoun-Ah Kim³ and Kichul Shin⁴, ¹Bucheon St. Mary's Hospital, Division of rheumatology, Department of Internal Medicine, College of Medicine, The Catholic University of Korea, Bucheon, Korea, Republic of (South), ²Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South), ³Department of Rheumatology, Ajou University School of Medicine, Suwon, Korea, Republic of (South), ⁴Kyungnam villa #102, Division of Rheumatology, Department of Internal Medicine, SMG-SNU Boramae Medical Center, Seoul, Korea, Republic of (South)
Background/Purpose: Herpes zoster (HZ) infection is not uncommon in rheumatoid arthritis (RA) patients, especially in those treated with biologic or targeted synthetic (bts) disease-modifying antirheumatic…
Abstract Number: 2843 • 2018 ACR/ARHP Annual Meeting
Leflunomide in Giant Cell Arteritis and Polymyalgia Rheumatica: A Real World Single Centre Experience
Faidra Laskou¹, Fiona Coath¹, Arslan Sidhu², Alam Wahid¹ and Bhaskar Dasgupta³, ¹Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Southend-On-Sea, United Kingdom, ²Rheumatology, Southend University Hospital NHS Foundation Trust, Southend, UK, Southend-on-Sea, United Kingdom, ³Southend University Hospital NHS Foundation Trust, Westcliff-on-Sea, United Kingdom
Background/Purpose: LEF could be the favourable DMARD for PMR/GCA due to inhibitory activity on dendritic cells and IL-6. Previous case series have shown efficacy of…
Abstract Number: 622 • 2018 ACR/ARHP Annual Meeting
DMARD Withdrawal in RA Patients Achieving Therapeutic Response with Certolizumab Pegol Combined with Dmards: Results from a Canadian Randomized Study
Janet E. Pope¹, Emmanouil Rampakakis², Julie Vaillancourt², Eric Grant³, Louis Bessette⁴, Juris Lazovskis⁵, Boulos Haraoui⁶ and John S. Sampalis⁷, ¹Department of Medicine, University of Western Ontario, London, ON, Canada, ²JSS Medical Research, Montreal, QC, Canada, ³Private Practice, Saint John, NB, Canada, ⁴Laval University, Québec, QC, Canada, ⁵Riverside Professional Centre, Sydney, NS, Canada, ⁶Institut de Rhumatologie de Montreal, Montreal, QC, Canada, ⁷McGill University, Montreal, QC, Canada
Background/Purpose: The efficacy and safety of certolizumab pegol (CZP) in the treatment of adult patients with moderate to severe rheumatoid arthritis (RA), when administered either…
Abstract Number: 1522 • 2018 ACR/ARHP Annual Meeting
Time Dependent Effect of Biologic Therapy on Overall Survival in Patients with Rheumatoid Arthritis and Cancer
Xerxes Pundole¹, Natalia Zamora², Harish Siddhanamatha³, Jean Tayar⁴, Cheuk Hong Leung⁵, Heather Lin⁶ and Maria Suarez-Almazor⁷, ¹Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ²Reumatologia, Instituto de Rehabilitación Psicofísica, Buenos Aires, Argentina, Buenos Aires, Argentina, ³The University of Texas Health Science Center, School of Biomedical Informatics, Houston, TX, USA, Houston, TX, ⁴Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas, USA, Houston, TX, ⁵Department of Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁶Biostatistics, Department of Biostatistics, The University of Texas MD Anderson Cancer Center, Houston, TX, USA, Houston, TX, ⁷Section of Rheumatology and Clinical Immunology, Department of General Internal Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Background/Purpose: Biologic disease-modifying anti-rheumatic drugs (bDMARDs) are commonly used in the treatment of rheumatoid arthritis (RA). But the use of bDMARDs in patients with RA…
Abstract Number: 2456 • 2018 ACR/ARHP Annual Meeting
Risk of Venous Thromboembolism in Rheumatoid Arthritis Patients in Truven Marketscan Data (Jan 2010–Sept 2015) Treated with Biologic or Conventional Dmards
Claudia A. Salinas¹, Lucy Mitchell², Jon T. Giles³, Thomas Dörner⁴ and Stephen P. Motsko¹, ¹Eli Lilly and Company, Indianapolis, IN, ²Eli Lilly and Company, Indianapols, IN, ³Columbia University, College of Physicians and Surgeons, New York, NY, ⁴Charité Universitätsmedizin Berlin and Deutsches Rheuma-Forschungszentrum (DRFZ), Berlin, Germany
Background/Purpose: Patients with RA have an increased risk of venous thromboembolism (VTE), including pulmonary embolism (PE) and deep vein thrombosis (DVT) compared to non-RA populations1. …
Abstract Number: 2875 • 2018 ACR/ARHP Annual Meeting
Identifying Trends in Lines of Therapy Following Initial Biologic Disease-Modifying Antirheumatic Drug in Patients with Rheumatoid Arthritis
Jay Lin¹, Jeannie Choi², Jeffrey R. Curtis³, Melissa Lingohr-Smith¹ and Susan Boklage⁴, ¹Novosys Health, Green Brook, NJ, ²Sanofi, Bridgewater, NJ, ³University of Alabama at Birmingham, Birmingham, AL, ⁴Regeneron Pharmaceuticals, Inc., Tarrytown, NY
Background/Purpose: Among patients with rheumatoid arthritis (RA) who have an inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs), the addition of a biologic DMARD…
Abstract Number: 636 • 2018 ACR/ARHP Annual Meeting
Remission/Low Disease Activity Is a Reasonable Treatment Target in Psa: Results from a Routine Care European Cohort of Psa Patients Treated with Ustekinumab or TNF Inhibitors
Laure Gossec^1,2, Paul Bergmans³, Kurt de Vlam⁴, Elisa Gremese⁵, Beatriz E. Joven⁶, Tatiana Korotaeva⁷, Michael Nurmohamed^8,9, Petros Sfikakis¹⁰, Stefan Siebert¹¹, Pavel Smirnov¹², Elke Theander¹³ and Josef S. Smolen¹⁴, ¹Rheumatology, Pitié Salpêtrière Hospital, Paris, France, ²Rheumatology, Sorbonne Université, Paris, France, ³Biometrics, Janssen-Cilag B.V., Breda, Netherlands, ⁴University Hospitals Leuven, Leuven, Belgium, ⁵Division of Rheumatology, Fondazione Policlinico Universitario A.Gemelli IRCCS, Catholic University of the Sacred Heart, Rome, Italy, ⁶Hospital Universitario 12 de Octubre, Madrid, Spain, ⁷Nasonova Research Institute of Rheumatology, Moscow, Russian Federation, ⁸Rheumatology, VU University Medical Center, Amsterdam, Netherlands, ⁹Amsterdam Rheumatology and Immunology Center | Reade, Amsterdam, Netherlands, ¹⁰Rheumatology Unit, 1st Dept. of Propaedeutic Internal Medicine, Joined Academic Rheumatology Program, Athens University Medical School, Athens, Greece, ¹¹Institute of Infection, Immunity and Inflammation, University of Glasgow, Cardiff, United Kingdom, ¹²Biometrics, Janssen-Cilag B.V., Moscow, Russian Federation, ¹³Biometrics, Janssen-Cilag B.V., Solna, Sweden, ¹⁴Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria
Background/Purpose: The link between treatment recommendations for PsA (to aim for a state of remission or low disease activity (LDA))1,2 and patient-important outcomes has been…
Abstract Number: 1526 • 2018 ACR/ARHP Annual Meeting
Baseline Characteristics and Outcomes in Patients with Anemia in Clinical Studies of Tofacitinib
Burkhard Moeller¹, Axel Finckh², Jose Maria Alvaro-Gracia³, Godehard Scholz¹, Daniel Aletaha⁴, Francesca Biondo⁵, Sander Strengholt⁶, Jose L Rivas⁷, Carol A Connell⁸ and Harry Shi⁹, ¹Inselspital-University Hospital, Bern, Switzerland, ²University Hospital of Geneva, Geneva, Switzerland, ³Hospital Universitario de La Princesa, Madrid, Spain, ⁴Medical University of Vienna, Vienna, Austria, ⁵Pfizer Inc, Rome, Italy, ⁶Pfizer Inc, Capelle aan den IJssel, Netherlands, ⁷Pfizer SLU, Madrid, Spain, ⁸Pfizer Inc, Groton, CT, ⁹Pfizer Inc, Collegeville, PA
Background/Purpose: Tofacitinib is an oral Janus kinase inhibitor for the treatment of RA. The purpose of this study is to describe the profile of patients…
Abstract Number: 2461 • 2018 ACR/ARHP Annual Meeting
Analysis of Severe Adverse Drug Reactions to Disease Modifying Drugs in an Inception Rheumatoid Arthritis Cohort
Zulema Rosales Rosado^1,2, Judit Font Urgelles¹, Pia Mercedes Lois¹, Cristina Vadillo Font¹, Dalifer Freites Núñez², Isabel Hernández-Rodríguez¹, Juan A Jover Jover¹ and Lydia A Alcazar², ¹Rheumatology, Hospital Clínico San Carlos, Madrid, Spain, ²Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain
Background/Purpose: There is a well-known risk of developing adverse drug reactions (ADR) in rheumatic patients due, mainly, to the Disease Modifying Drugs (DMARD) widely used.…
Abstract Number: 2878 • 2018 ACR/ARHP Annual Meeting
Phase II Clinical Trials Systematically Overestimate Treatment Effects of Subsequent Phase III Trials in Rheumatoid Arthritis
Andreas Kerschbaumer¹, Harald Herkner², Josef S. Smolen³ and Daniel Aletaha⁴, ¹Department of Internal Medicine III, Division of Rheumatology, Medical University of Vienna, Vienna, Austria, ²Department for Emergency Medicine, Medical University of Vienna, Vienna, Austria, ³Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, Vienna, Austria, ⁴Medical University of Vienna, Vienna, Austria
Background/Purpose: Phase 3 (P3) clinical trials are the mainstay of drug development in all areas of medicine, including rheumatology, allowing to determine safety and efficacy…
Abstract Number: 681 • 2018 ACR/ARHP Annual Meeting
Identification of Treatment Naïve Patients with Psoriatic Arthritis Who Will Require a TNF Inhibitor
Dan Gromer¹, Laura C. Coates², Oliver FitzGerald³, Blanca Himes⁴, Philip Helliwell⁵ and Alexis Ogdie⁶, ¹University of Pennsylvania, Medical Student, Philadelphia, PA, ²University of Oxford, Oxford, United Kingdom, ³Department of Rheumatology, St Vincent's University Hospital and Conway Institute, University College Dublin, Ireland, Dublin, Ireland, ⁴Biostatistics and Epidemiology, University of Pennsylvania, Philadelphia, PA, ⁵LIMM, Section of Musculoskeletal Disease, University of Leeds, Leeds, United Kingdom, ⁶Medicine/Rheumatology and Epidemiology, University of Pennsylvania, Philadelphia, PA
Background/Purpose: Psoriatic arthritis (PsA) is a heterogeneous chronic inflammatory disease that affects the skin, joints, and soft tissues. No metrics exist to indicate whether an…
Abstract Number: 1538 • 2018 ACR/ARHP Annual Meeting
Moderate Adverse Drug Reactions Due to Disease Modifying Drugs in a Cohort of Patients with Incident Rheumatoid Arthritis
Lydia A Alcazar¹, Dalifer Freites Núñez¹, Isabel Hernández-Rodríguez², Judit Font Urgelles², Pia Mercedes Lois², Benjamín Fernández-Gutiérrez², Juan A Jover Jover¹ and Zulema Rosales Rosado^1,2, ¹Instituto de Investigación Sanitaria San Carlos (IdISSC), Madrid, Spain, ²Rheumatology, Hospital Clínico San Carlos, Madrid, Spain
Background/Purpose: In rheumatology, we are aware of the possibility to develop adverse drug reactions (ADR) to the widely used Disease Modifying Drugs (DMARD). We are…
Abstract Number: 2464 • 2018 ACR/ARHP Annual Meeting
Clinimetric and Drug Use Differences in Colombian Patients with Early and Established Rheumatoid Arthritis
Jorge Florez-Suarez¹, Paul Mendez², Edna Bermudez¹, Paola Coral² and Gerardo Quintana-Lopez^1,3, ¹Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogotá, Colombia, ²Department of Rheumatology, Fundación Santa Fe de Bogotá University Hospital, Bogota, Colombia, ³School of medicine, Universidad Nacional de Colombia, Bogotá, Colombia
Background/Purpose: Current guidelines for RA treatment are focused on the importance of defining the duration of symptoms before diagnosis to achieve better outcomes. This concept…

« Previous Page
1
…
3
4
5
6
7
…
24
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].